- Home
- ALVO vs ADNT Comparison
ALVO vs ADNT Comparison
Compare ALVO & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALVO | ADNT |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Luxembourg | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ALVO | ADNT |
|---|---|---|
| Price | $5.40 | $20.75 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 10 |
| Target Price | $9.25 | ★ $23.10 |
| AVG Volume (30 Days) | 366.8K | ★ 1.3M |
| Earning Date | 11-12-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | $573,350,000.00 | ★ $14,535,000,000.00 |
| Revenue This Year | $20.85 | $1.86 |
| Revenue Next Year | $44.49 | $2.20 |
| P/E Ratio | $22.36 | ★ N/A |
| Revenue Growth | ★ 45.55 | N/A |
| 52 Week Low | $4.32 | $10.04 |
| 52 Week High | $13.08 | $26.16 |
Technical Indicators
Market Signals| Indicator | ALVO | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 48.61 |
| Support Level | $5.21 | $21.18 |
| Resistance Level | $5.58 | $22.45 |
| Average True Range (ATR) | 0.21 | 0.95 |
| MACD | 0.08 | -0.13 |
| Stochastic Oscillator | 82.80 | 13.08 |
Price Performance
Historical ComparisonAbout ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.